Amplia Therapeutics (ASX:ATX) reported an additional confirmed partial response in its ongoing ACCENT clinical trial evaluating the focal adhesion kinase inhibitor narmafotinib alongside standard chemotherapy, according to a Friday Australian bourse filing.
A confirmed partial response is defined as a tumor shrinkage exceeding 30%, sustained for at least two months, with no new lesions detected, the filing said.
The update lifts the objective response rate to 31%, surpassing the 23% benchmark seen with chemotherapy alone, the filing added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。